GCIP Inhibitors
Chemical inhibitors of GCIP can function through various mechanisms to reduce the protein's activity within cellular signaling pathways. Staurosporine, a well-known kinase inhibitor, can inhibit the activity of protein kinases that are potentially involved in the phosphorylation of GCIP, which is crucial for its role in cell cycle regulation. A similar mechanism is employed by U0126 and PD98059, which target MEK enzymes in the MAPK/ERK pathway, potentially reducing the phosphorylation and hence the activity of GCIP. The inhibition of this pathway can result in a decrease in the functional activity of GCIP, as the MAPK/ERK pathway is integral to cell cycle progression and GCIP's role within it. SB203580 and SP600125 target different kinases within the MAPK pathway, namely p38 MAPK and JNK, respectively. By inhibiting these kinases, the chemical inhibitors can disrupt the signaling cascades that may affect GCIP's regulatory functions.
Rapamycin and Wortmannin act upon the PI3K/AKT/mTOR pathway, a pathway known to play a significant role in cell growth and proliferation, which GCIP is believed to influence. Rapamycin's inhibition of mTOR and Wortmannin's inhibition of PI3K can lead to a decrease in the functional activity of GCIP by altering the phosphorylation state of key proteins involved in the cell cycle. Triciribine, another AKT inhibitor, works in a similar fashion by reducing AKT activity and thereby influencing GCIP function. Roscovitine and Alsterpaullone inhibit CDKs, which are vital for the progression of the cell cycle, and as GCIP is thought to be involved in cell cycle control, the inhibition of CDKs can lead to reduced activity of GCIP. Lastly, PD0325901, by selectively inhibiting MEK, can affect the MAPK/ERK signaling pathway, which is known to regulate various aspects of cell cycle progression, thereby influencing GCIP's role in these processes. Each of these inhibitors acts upon specific enzymes and pathways that are crucial for the proper functioning of GCIP in various cellular contexts, leading to its functional inhibition.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. GCIP, as a cell cycle regulator, may be functionally inhibited by staurosporine due to its ability to inhibit kinases that could phosphorylate GCIP, thereby regulating its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Since PI3K signaling can impact cell cycle progression in which GCIP is involved, inhibition of PI3K could lead to reduced activation of downstream targets that may include GCIP. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a known inhibitor of p38 MAPK. The p38 MAPK pathway is involved in stress responses and cell cycle control, which could affect the function of GCIP in regulating the cell cycle. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK pathway is implicated in controlling numerous cellular processes including those that GCIP may influence. Inhibition of JNK could lead to an indirect functional inhibition of GCIP. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 functions as an inhibitor of MEK, which is upstream of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 could hinder the phosphorylation state of GCIP, affecting its functional role in the cell cycle. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is a central regulator of cell growth and proliferation, processes in which GCIP is potentially involved. Inhibition of mTOR could thus indirectly reduce GCIP functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, and by inhibiting PI3K, it could lead to a decrease in the phosphorylation of proteins involved in the cell cycle, potentially including GCIP. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a cyclin-dependent kinase (CDK) inhibitor. CDKs are key regulators of the cell cycle, and GCIP's activity could be impacted by the changes in CDK activity due to roscovitine. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor. Since AKT is a major signaling molecule downstream of PI3K and is involved in cell cycle progression, its inhibition could reduce the functional activity of GCIP. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDKs, including CDK1, CDK2, and CDK5. As CDKs regulate the cell cycle and GCIP is involved in cell cycle control, inhibition of CDK by alsterpaullone could inhibit GCIP function. | ||||||